Company
Indi Molecular
Small Molecule Oncology Therapeutics Built with Antibody Surrogates
Also known as Indi Molecular, Inc
- Status
- Operatingas of 2026-09-18
- Business model
- B2B
- Legal name
- Indi Molecular, Inc
Claim, correct or request removal
Record updated 29 September 2026
About
Indi Molecular® has developed synthetic small molecule targeted oncology therapeutics against overexpressed folate receptors in ovarian cancer and KRAS G12D expressing pancreatic cancers. We created these therapeutic molecules using a breakthrough, synthetic protein chemistry platform: Protein Catalyzed Capture (PCC) agents. These targeted therapeutics are small synthetic peptide replacements for antibody-based therapeutics.
Funding snapshot
- Total raised
- $4.5MSEC form D sum, as of 2026-09-29Source (opens in a new tab)
- Latest round
- Round, $4.5M2017-06-06
Funding rounds
- Round, 2017
- $4.5M2017-06-06, SEC form D sold, 6 investors
Loading relationship preview